Seminal vesicles

Global Liquid Biopsy Market Analysis & Forecasts, 2021-2022 & 2032 - Focus on Offering, Usage, Workflow, Circulating Biomarker, Sample, Technology, Clinical Application, End User - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022
Health, Oncology, Medical Supplies, CAGR, TSO, Data analysis, Cancer, LDT, Laboratory, RNA, Liquid biopsy, Therapy, Seminal vesicles, COVID-19, Melanoma, Prostate cancer, Safety, New product development, QIAGEN, Government, Exosome, Workflow, Recurrence, Thyroid cancer, Adoption, Research, Nanjing Sample Technology, Informatics, Growth, Region, DNA, Nucleic acid thermodynamics, Sysmex Corporation, Physician, Bristol Myers Squibb, Biotechnology, NGS, Investment, Health, Chinese, Academy, Molecular Cancer Research, Illumina, Inc., Lung cancer, RUO, Neoplasm, Clinical Laboratory Improvement Amendments, NSCLC, Awareness, PCR, Prevalence, City, Breast cancer, Large-cell lung carcinoma, Medical imaging, Fine chemical, Uranium, Pharmaceutical industry, Beauty salon, Biomarker, Technology, EMEA

The North America region is expected to dominate the global liquid biopsy market during the forecast period 2022-2032.

Key Points: 
  • The North America region is expected to dominate the global liquid biopsy market during the forecast period 2022-2032.
  • Increasing investments in R&D of liquid biopsy products and services and various research fundings is one of the major opportunities in the global liquid biopsy market.
  • The current global liquid biopsy market comprises various indications such as lung cancer, breast cancer, prostate cancer, and many others.
  • End User (Academic and Research Institutions, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, Other End Users)
    The academic and research institutions segment dominates the global liquid biopsy market.

STRM.BIO Appoints Vanessa Salazar as Vice President of Business Development

Retrieved on: 
Monday, June 13, 2022
Spark Therapeutics, EV, VC, Time, GlaxoSmithKline, Hematology, Business development, CEO, Partnership, RNA, Rutgers University, Founder, Therapy, Multimedia, Growth, Patient, Stem cell, DNA, Passage, Corporate development, Medicine, Degenerative disease, Seminal vesicles, EVS, Pharmaceutical industry

BOSTON, June 13, 2022 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies, and developing new therapeutics for rare blood diseases, announced today the appointment of Vanessa Salazar as Vice President of Business Development. Mrs. Salazar is a skilled corporate development executive with more than twenty years of experience in the biopharmaceutical industry including time with Passage Bio, Spark Therapeutics, and GlaxoSmithKline. Her expertise spans strategic and operational aspects of business development, alliance management, medical affairs, and clinical development. Mrs. Salazar is joining a growing business development team and advisory board at STRM.BIO, which reflects the company's increased momentum in pursuing partnership opportunities. 

Key Points: 
  • BOSTON, June 13, 2022 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies, and developing new therapeutics for rare blood diseases, announced today the appointment of Vanessa Salazar as Vice President of Business Development.
  • Mrs. Salazar is a skilled corporate development executive with more than twenty years of experience in the biopharmaceutical industry including time with Passage Bio, Spark Therapeutics, and GlaxoSmithKline.
  • Her expertise spans strategic and operational aspects of business development, alliance management, medical affairs, and clinical development.
  • Mrs. Salazar is joining a growing business development team and advisory board at STRM.BIO, which reflects the company's increased momentum in pursuing partnership opportunities.

Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting

Retrieved on: 
Friday, May 27, 2022
Research, Medical Devices, Women, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, Cancer, Serum, Risk, Breast, DNA, Blood, Neoplasm, Annual general meeting, Mercy, Abstract, Patient, Woman, Prostate, Quality of life, Ovarian cancer, Society, American Society of Clinical Oncology, National Institutes of Health, Trial of the century, Method, CA125, Plasma, Lung cancer, EVS, Seminal vesicles, III, Biomarker, ASCO, National, Diagnosis, Computational biology, Medical imaging, Birth control

The study, titled Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer, will be presented on Saturday, June 4, 2022, at ASCO by Daniel Gusenleitner, Ph.D., Head of Computational Biology for Mercy Bioanalytics (Abstract #5542).

Key Points: 
  • The study, titled Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer, will be presented on Saturday, June 4, 2022, at ASCO by Daniel Gusenleitner, Ph.D., Head of Computational Biology for Mercy Bioanalytics (Abstract #5542).
  • The Mercy Halo OC assay is designed to detect stage I/II ovarian cancer and to distinguish cancer from benign conditions.
  • We look forward to expanding our studies of the Mercy Halo Ovarian Cancer assay to include average risk, asymptomatic women who might benefit from an improved ovarian cancer screening paradigm.
  • Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer.

Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Doxorubicin, PBS, Organic acid, Lysosomal storage disease, Engineering, Transferrin, Company, International Society, Spleen, ISEV, Neoplasm, International Society for Extracellular Vesicles, ERT, Seminal vesicles, Endothelium, Ligand, Inflammation, Antibody, Therapy, E-selectin, Exosome, GAA, Half-life, Liver, Degenerative disease, Comparison, ABS, Neutralizing antibody, Cell, Cell biology, Mouse, Glycogen storage disease type II, CNS, Brain, Plasma, EVS, BBB, FC, RNA, Central nervous system, Technology, South Luzon Expressway, Enzyme replacement therapy, Trehalose, Protein, Oxford, GLOBE, Tissue, Muscle, Pharmaceutical industry, Wood drying, Vaccine, Fine chemical

In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.

Key Points: 
  • In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.
  • We believe our advances will allow exosome therapeutics access to cellular compartments and tissues that are currently out of reach using other approaches.
  • This could provide significant benefit for both creating feasible dosing regimens and to ensure sufficient plasma residence time for tissue-specific targeting.
  • Engineered display of ligands on the surface of exosomes can be used to increase specific targeting of exosomes to desired tissues.

Evox Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Retrieved on: 
Tuesday, May 24, 2022
Engineering, EDT, Therapy, Degenerative disease, Cell, Exosome, Brain, EVS, Conference, Seminal vesicles, RNA, Technology, Central nervous system, Oxford, Tissue, GLOBE, Medical device, Vaccine, Pharmaceutical industry

OXFORD, United Kingdom, May 24, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, will participate in the 2022 Jefferies Healthcare Conference June 8-10, 2022.

Key Points: 
  • OXFORD, United Kingdom, May 24, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, will participate in the 2022 Jefferies Healthcare Conference June 8-10, 2022.
  • Antonin de Fougerolles, Ph.D., Chief Executive Officer of Evox Therapeutics, will present on Friday, June 10 at 11:30 a.m. EDT and will host 1x1 meetings at and around the conference in New York.
  • Evox uses its proprietary DeliverEXtechnology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system.
  • Evox is backed by leading life sciences venture capital groups including Redmile and Orbimed, and is supported by a comprehensive intellectual property portfolio.

Evox Therapeutics Announces Data Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Retrieved on: 
Thursday, May 19, 2022
Exosome, Brain, Engineering, Therapy, Tissue, EVS, Seminal vesicles, Degenerative disease, RNA, Central nervous system, Technology, Cell, Vaccine

Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, to develop an entirely new class of therapeutics for the treatment of severe rare diseases.

Key Points: 
  • Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, to develop an entirely new class of therapeutics for the treatment of severe rare diseases.
  • Evox uses its proprietary DeliverEXtechnology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system.
  • Exosome-based drugs have the potential to address some of the limitations of protein, RNA, and gene therapy-based therapies by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies.
  • Evox is backed by leading life sciences venture capital groups including Redmile and Orbimed,and is supported by a comprehensive intellectual property portfolio.

Global Acellular Therapy Market Report 2022: Strategies and Applications with Focus on Application, Pipeline, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 19, 2022
Health, Stem Cells, Regenerative medicine, Traction, Survival, Transplant, Lipid, SC, MicroRNA, COVID-19, Cell, Research, Method, Industry, Human, EVS, Perception, Seminal vesicles, Physiology, Competitive landscape, Gaps, Pathology, RNA transfection, Regeneration, Adoption, Protein, Stem cell, Growth, Cancer, ScS, Lists of diseases, Tissue, Vaccine, Pharmaceutical industry, Healthcare

The "Global Acellular Therapy Market - Strategies and Applications: Focus on Application, Pipeline, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acellular Therapy Market - Strategies and Applications: Focus on Application, Pipeline, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
  • What are the strategies and methods of implementation in the acellular therapy industry which can affect the future perception of the market?
  • Which regulatory procedures are required to unify the approval process for the emerging acellular therapy market?
  • What are the gaps in regularizing acellular therapy market adoption in regular healthcare routines, and how are these gaps being tackled?

International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics’ Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution

Retrieved on: 
Monday, May 9, 2022
Brain, Karolinska Institute, Exosome, GLOBE, RNA, Engineering, Oxford, Cell, ISCT, Degenerative disease, Delivery, Gene editing, Therapy, EVS, Tissue, ISEV, Science, Technology, International Society, Neoplasm, Seminal vesicles, Central nervous system, Medical device

OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.

Key Points: 
  • OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.
  • The presentations were part of the ISCT 1-day Scientific Signature series Therapeutic Advances with Native and Engineered Human EVs.
  • Samir El Andaloussi, Ph.D., Evox co-founder and Professor at the Karolinska Institut, presented on EV Engineering for Directed Loading and Delivery of Biotherapeutics.
  • Evox is backed by leading life sciences venture capital groups including Redmile and Orbimed, and is supported by a comprehensive intellectual property portfolio.

uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Monday, May 2, 2022
Haemophilia, NASDAQ, GLOBE, CNS, MicroRNA, C9orf72, Cell, AAV, Seminal vesicles, Doctor of Philosophy, Patient, Gene, American Society of Gene and Cell Therapy, Huntington's disease, Fabry disease, Society, Abstract, Technology, Research, Annual general meeting, ALS, Pharmaceutical industry, Medical device

and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.

Key Points: 
  • and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.
    "Our presentations at ASGCT showcase the exceptional work of our uniQure scientists and the breadth of our research pipeline as we advance our investigational AAV gene therapy programs, stated Ricardo Dolmetsch, Ph.D. president of research and development at uniQure.
  • We are particularly proud of our studiesdemonstrating the potential of the linQURE cargo platform, delivering multiple miRNAs in a single AAV and its application to selectively silence mutant C9orf72 in an ALS preclinical model.
  • Specific details on uniQures presentations taking place at ASGCT include:
    Presenter: Astrid Valles-Sanchez, Ph.D. director of CNS disease biology, uniQure
    Title: Functional transfer of engineered microRNAs through extracellular vesicles: An in vitro proof-of-mechanism study in Huntingtons disease models (Abstract #590)
    uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.
  • We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases.

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

Retrieved on: 
Thursday, April 28, 2022
Cooperative research and development agreement, Gian Maria Annovi, NYSE, U.S. Securities and Exchange Commission, CEO, LinkedIn, EVS, Plasma, Pharmacokinetics, National Institute on Aging, Down syndrome, PD, Blood, Cerebrospinal fluid, CSF, Parkinson's disease, Neurodegeneration, Twitter, Patient, Cell death, Alzheimer's disease, Risk, National Institute, Memory, Seminal vesicles, Human, Toxicity, Forward-looking statement, AD, Axonal transport, Biomarker, Company, Development, Annual report, Security (finance), Brain, National, EV, Cognition, CRADA, NIA, Medical imaging, Ageing

Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap

Key Points: 
  • Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a part of the National Institutes of Health.
  • Biomarkers will be assessed in de-identified plasma and CSF samples of Alzheimer's Disease (AD), Parkinson's disease (PD), and control participants from Annovis' Phase 2a clinical trials.
  • "We are extremely pleased to collaborate with Dr. Dimitrios Kapogiannis and his esteemed colleagues at the National Institute on Aging," said Maria L. Maccecchini, Ph.D., Founder, President, and CEO.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .